Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II.
Glycogen storage disease type II (GSDII) or Pompe disease is an autosomal recessive disorder caused by defects in the acid alpha-glucosidase gene, which leads to lysosomal glycogen accumulation and enlargement of the lysosomes mainly in cardiac and muscle tissues, resulting in fatal hypertrophic cardiomyopathy and respiratory failure in the most severely affected patients. Enzyme replacement therapy has already proven to be beneficial in this disease, but correction of pathology in skeletal muscle still remains a challenge. As substrate deprivation was successfully used to improve the phenotype in other lysosomal storage disorders, we explore here a novel therapeutic approach for GSDII based on a modulation of muscle glycogen synthesis. Short hairpin ribonucleic acids (shRNAs) targeted to the two major enzymes involved in glycogen synthesis, i.e. glycogenin (shGYG) and glycogen synthase (shGYS), were selected. C2C12 cells and primary myoblasts from GSDII mice were stably transduced with lentiviral vectors expressing both the shRNAs and the enhanced green fluorescent protein (EGFP) reporter gene. Efficient and specific inhibition of GYG and GYS was associated not only with a decrease in cytoplasmic and lysosomal glycogen accumulation in transduced cells, but also with a strong reduction in the lysosomal size, as demonstrated by confocal microscopy analysis. A single intramuscular injection of recombinant AAV-1 (adeno-associated virus-1) vectors expressing shGYS into newborn GSDII mice led to a significant reduction in glycogen accumulation, demonstrating the in vivo therapeutic efficiency. These data offer new perspectives for the treatment of GSDII and could be relevant to other muscle glycogenoses.
Douillard-Guilloux
Gaelle
G
Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris, France.
Raben
Nina
N
Takikita
Shoichi
S
Batista
Lionel
L
Caillaud
Catherine
C
Richard
Emmanuel
E
D000818:Animals; D000831:Animals, Newborn; D002460:Cell Line; D000229:Dependovirus / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors / Q000235:genetics; D006003:Glycogen / Q000096:biosynthesis* / Q000235:genetics*; D006009:Glycogen Storage Disease Type II / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D006006:Glycogen Synthase / Q000037:antagonists & inhibitors / Q000235:genetics; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D034622:RNA Interference / Q000502:physiology*
D006023:Glycoproteins; C051887:glycogenin; D006003:Glycogen; D005964:Glucosyltransferases; D006006:Glycogen Synthase